Spectrum announced that Rolvedon has been added to the latest National Comprehensive Cancer Network Supportive Care Guidelines, or NCCN Guidelines, in oncology for Hematopoietic Growth Factors. The NCCN Guidelines provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia and now include Rolvedon as a treatment option under Management of Neutropenia: G-CSFs for Prophylaxis of Febrile Neutropenia and Maintenance of Scheduled Dose Delivery.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SPPI: